Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost +/- hyperthermia for glioblastoma multiforme
- PMID: 9457811
- DOI: 10.1016/s0360-3016(97)00731-1
Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost +/- hyperthermia for glioblastoma multiforme
Abstract
Purpose: To determine if adjuvant interstitial hyperthermia (HT) significantly improves survival of patients with glioblastoma undergoing brachytherapy boost after conventional radiotherapy.
Methods and materials: Adults with newly-diagnosed, focal, supratentorial glioblastoma < or = 5 cm in diameter were registered postoperatively on a Phase II/III randomized trial and treated with partial brain radiotherapy to 59.4 Gy with oral hydroxyurea. Those patients whose tumor was still implantable after teletherapy were randomized to brachytherapy boost (60 Gy at 0.40-0.60 Gy/h) +/- HT for 30 min immediately before and after brachytherapy. Time to progression (TTP) and survival from date of diagnosis were estimated using the Kaplan-Meier method.
Results: From 1990 to 1995, 112 eligible patients were entered in the trial. Patient ages ranged from 21-78 years (median, 54 years) and KPS ranged from 70-100 (median, 90). Most commonly due to tumor progression or patient refusal, 33 patients were never randomized. Of the patients, 39 were randomized to brachytherapy ("no heat") and 40 to brachytherapy + HT ("heat"). By intent to treat, TTP and survival were significantly longer for "heat" than "no heat" (p = 0.04 and p = 0.04). For the 33 "no heat" patients and 35 "heat" patients who underwent brachytherapy boost, TTP and survival were significantly longer for "heat" than "no heat" (p = 0.045 and p = 0.02, respectively; median survival 85 weeks vs. 76 weeks; 2-year survival 31% vs. 15%). A multivariate analysis for these 68 patients adjusting for age and KPS showed that improved survival was significantly associated with randomization to "heat" (p = 0.008; hazard ratio 0.51). There were no Grade 5 toxicities, 2 Grade 4 toxicities (1 on each arm), and 7 Grade 3 toxicities (1 on "no heat" and 6 on the "heat" arm).
Conclusion: Adjuvant interstitial brain HT, given before and after brachytherapy boost, after conventional radiotherapy significantly improves survival of patients with focal glioblastoma, with acceptable toxicity.
Similar articles
-
High-dose-rate stereotactic brachytherapy for patients with newly diagnosed glioblastoma multiformes.J Neurooncol. 2003 Jan;61(1):45-55. doi: 10.1023/a:1021270201988. J Neurooncol. 2003. PMID: 12587795 Review.
-
Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy.Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):1133-9. doi: 10.1016/j.ijrobp.2004.12.032. Int J Radiat Oncol Biol Phys. 2005. PMID: 15990019
-
Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):71-7. doi: 10.1016/s0360-3016(00)01458-9. Int J Radiat Oncol Biol Phys. 2001. PMID: 11163499 Clinical Trial.
-
Interstitial irradiation versus interstitial thermoradiotherapy for supratentorial malignant gliomas: a comparative survival analysis.Int J Radiat Oncol Biol Phys. 1994 Oct 15;30(3):591-600. doi: 10.1016/0360-3016(92)90945-e. Int J Radiat Oncol Biol Phys. 1994. PMID: 7928490 Clinical Trial.
-
Interstitial brachytherapy procedures for brain tumors.Semin Surg Oncol. 1997 May-Jun;13(3):157-66. doi: 10.1002/(sici)1098-2388(199705/06)13:3<157::aid-ssu2>3.0.co;2-6. Semin Surg Oncol. 1997. PMID: 9143053 Review.
Cited by
-
Feasibility of removable balloon implant for simultaneous magnetic nanoparticle heating and HDR brachytherapy of brain tumor resection cavities.Int J Hyperthermia. 2020;37(1):1189-1201. doi: 10.1080/02656736.2020.1829103. Int J Hyperthermia. 2020. PMID: 33047639 Free PMC article.
-
High-dose-rate stereotactic brachytherapy for patients with newly diagnosed glioblastoma multiformes.J Neurooncol. 2003 Jan;61(1):45-55. doi: 10.1023/a:1021270201988. J Neurooncol. 2003. PMID: 12587795 Review.
-
Low-dose rate stereotactic iodine-125 brachytherapy for the treatment of inoperable primary and recurrent glioblastoma: single-center experience with 201 cases.J Neurooncol. 2014 Dec;120(3):615-23. doi: 10.1007/s11060-014-1595-y. Epub 2014 Aug 24. J Neurooncol. 2014. PMID: 25151509
-
Radiobiological Evaluation of Combined Gamma Knife Radiosurgery and Hyperthermia for Pediatric Neuro-Oncology.Cancers (Basel). 2021 Jun 30;13(13):3277. doi: 10.3390/cancers13133277. Cancers (Basel). 2021. PMID: 34208909 Free PMC article.
-
Integrating Hyperthermia into Modern Radiation Oncology: What Evidence Is Necessary?Front Oncol. 2017 Jun 30;7:132. doi: 10.3389/fonc.2017.00132. eCollection 2017. Front Oncol. 2017. PMID: 28713771 Free PMC article. Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical